Ontology highlight
ABSTRACT: Background
The use of Escherichia coli purine nucleoside phosphorylase (PNP) to activate fludarabine has demonstrated safety and antitumor activity during preclinical analysis and has been approved for clinical investigation.Patients and methods
A first-in-human phase I clinical trial (NCT 01310179; IND 14271) was initiated to evaluate safety and efficacy of an intratumoral injection of adenoviral vector expressing E. coli PNP in combination with intravenous fludarabine for the treatment of solid tumors. The study was designed with escalating doses of fludarabine in the first three cohorts (15, 45, and 75 mg/m(2)) and escalating virus in the fourth (10(11)-10(12) viral particles, VP).Results
All 12 study subjects completed therapy without dose-limiting toxicity. Tum
SUBMITTER: Rosenthal EL
PROVIDER: S-EPMC4560028 | biostudies-literature | 2015 Jul
REPOSITORIES: biostudies-literature